<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "http://dtd.nlm.nih.gov/publishing/2.0/journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="2.0" xml:lang="EN">
  <front>    <journal-meta>
      <journal-title>Clinical Reviews and Opinions</journal-title>
      <issn pub-type="epub">2141-2553</issn>      <publisher>
        <publisher-name>Academic Journals</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.5897/CRO15.0098</article-id>
      <title-group>
        <article-title><![CDATA[Impact of seasonal malaria chemoprevention of sulphadoxineâ€“pyrimethamine plus amodiaquine on molecular markers resistance of Plasmodium falciparum malaria: A review in West Africa]]></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
        		        	<name name-style="western">
	            <surname>Hamma</surname>
            <given-names>Maiga</given-names>
	          </name>	
        	        </contrib>
      </contrib-group>
      <author-notes>
		<corresp id="cor1">* E-mail: <email xlink:type="simple">hmaiga@icermali.org</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
      	<day>30</day>
        <month>01</month>
        <year>2016</year>
      </pub-date>
      <history>
      			<date date-type="received">
			<day>08</day>
			<month>10</month>
			<year>2015</year>
		</date>
						<date date-type="accepted">
			<day>30</day>
			<month>12</month>
			<year>2016</year>
		</date>
			  </history>
      <volume>7</volume>
      <issue>1</issue>
	  	  <fpage>1</fpage>
	  <lpage>10</lpage>
      <permissions>
		<license xlink:type="simple">
			<license-p>
			This is an open-access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
			</license-p>
		</license>
	  </permissions>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/CRO/article-abstract/388202456910">
		This article is available from http://politicalwaffle.uk/journal/CRO/article-abstract/388202456910	  </self-uri>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/CRO/article-full-text-pdf/388202456910">
		The full text article is available as a PDF file from http://politicalwaffle.uk/journal/CRO/article-full-text-pdf/388202456910	  </self-uri>
	  
      <abstract><![CDATA[The study discuss the potential impact of seasonal malaria chemoprevention (SMC) on the cases of malaria, anaemia and molecular markers resistance Plasmodium falciparum malaria; and also review the mechanism of action and the effect on immunity of SMC. SMC using an efficacious drug is likely to substantially reduce cases of clinical malaria in high transmission settings. However, an increase of molecular markers could hamper rolling out SMC as a national policy.

	 

	Key words: Seasonal malaria chemoprevention impact, malaria molecular markers, review.]]></abstract>
    </article-meta>
  </front>
      <body/>
    <back>
		<ref-list>
			<title>References</title>
						<ref id="ref1">
				<label>1</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Alker AP, Kazadi WM, Kutelemeni AK, Bloland PB, Tshefu AK, Meshnick SR (2008). dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop. Med. Int. Health 13(11):1384-91.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref2">
				<label>2</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, Tanner M, Alonso PL (2007). Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 4:1259-67.]]>
				</mixed-citation>
			</ref>
						<ref id="ref3">
				<label>3</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Le Bras J, Deloron P (2003). DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J. Antimicrob. Chemother. 52(1):43-9.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref4">
				<label>4</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Barger B, Maiga H, Traore OB, Tekete M, Tembine I, Dara A, Traore ZI, Gantt S, Doumbo OK, Djimde AA (2009). Intermittent Preventive Treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop. Med. Int. Health 14(7):784-91.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref5">
				<label>5</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Beier JC, Killeen GF, Githure JI (1999). Short report: Entomologic inoculation rates and Plasmodium falciparum malaria prevalence in Africa. Am. J. Trop. Med. Hyg. 61(1):109-13.]]>
				</mixed-citation>
			</ref>
						<ref id="ref6">
				<label>6</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Berglez J, Iliades P, Sirawaraporn W, Coloe P, Macreadie I (2004). Analysis in Escherichia coli of Plasmodium falciparum dihydropteroate synthase (DHPS) alleles implicated in resistance to sulfadoxine. Int. J. Parasitol. 34(1):95-100.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref7">
				<label>7</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, Greenwood B (2010). A randomized trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One. 5:e11225.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref8">
				<label>8</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, Conway DJ, Jasseh M, Wiseman V, Milligan PJ, Greenwood B (2011). Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomized controlled trial. PLoS Med. 8(2):e1000409.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref9">
				<label>9</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Bruce-Chwatt LJ (1980). Essential malariology, vol. 354. William Heinemann Medical Books Ltd., London, United Kingdom.]]>
				</mixed-citation>
			</ref>
						<ref id="ref10">
				<label>10</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, Greenwood B, Chandramohan D (2008). Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS One. 3(5):e2227.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref11">
				<label>11</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Cairns M, Roca-Feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, Ghani AC, Greenwood BM (2012). Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat. Commun. 3:881.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref12">
				<label>12</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Chandramohan D, Owusu-Agyei S, Carneiro I, Awinw T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B (2005). Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 331(7519):727-33.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref13">
				<label>13</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I (2007). Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop. Med. Int. Health 12(6):743-50.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref14">
				<label>14</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Ciss B, Sokhna C, Boulanger D, Milet J, B el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF (2006). Seasonal intermittent preventive treatment with artesunate and sulfadoxinepyrimethamine for prevention of malaria in Senegalese children: a randomized, placebo-controlled, double-blind trial. Lancet 367:659-67.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref15">
				<label>15</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundiill B, Otido J, Crudder C, Estambale BB, Brooker S (2008). Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo- controlled trial. Lancet 372:127-38.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref16">
				<label>16</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Dicko A, Barry A, Dicko M, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Conar T, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B (2011). Malaria Morbidity in Children in the Year after They Had Received Intermittent Preventive Treatment of Malaria in Mali: A Randomized Control Trial. PLoS One. 6(8):e23390.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref17">
				<label>17</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, Toure OB, Sacko M, Doumbo OK (2008). Impact of intermittent preventive treatment with sulphadoxinepyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar. J. 7:123.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref18">
				<label>18</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Dieckmann A, Jung A (1986). The mechanism of pyrimethamine resistance in Plasmodium falciparum. Parasitology 93(Pt 2):275-8.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref19">
				<label>19</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O (2007). Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar. J. 6:80. Image
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref20">
				<label>20</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Lo AC, Ndiaye M, Sow D, De Sousa A, Gaye O (2011). Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol. Res. 109(1):133-8.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref21">
				<label>21</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Foote SJ, Galatis D, Cowman AF (1990). Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA. 87:3014-7.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref22">
				<label>22</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D (2009). Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 313(9700):1521-32.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref23">
				<label>23</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D (2008). Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar. J. 7:54.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref24">
				<label>24</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Greenwood B (2007). Intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45:26-28.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref25">
				<label>25</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Grobusch MP, Lell B, Schwarz NG (2007). Intermittent preventive treatment against malaria in infants in Gabon  a randomized, double blind, placebo-controlled trial. J. Infect. Dis. 196:1595-1602.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref26">
				<label>26</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF and Oduola AM (2005). Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 95:183-93.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref27">
				<label>27</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson PA, Abruquah HH, Kreuels B, Ayim M, Busch W, Marks F, Amoah K, Opoku E, Meyer CG, Adjei O, May J (2007). A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45(1):16-25.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref28">
				<label>28</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Konat AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansan A, Soulama I, Kangoy DT, Kabor Y, Ouedraogo A, Tiono AB, Ouedraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA (2011). Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomized, double blind, and placebo controlled trial. PLoS Med. 8(2):e1000408.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref29">
				<label>29</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV (2002). Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185:380-8.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref30">
				<label>30</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Kweku M, Liu D, Adjuik M, Binka F, Seidu M, Greenwood B, Chandramohan D (2008). Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE 3(12):e4000.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref31">
				<label>31</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Lo AC, Faye B, Ba el-H, Cisse B, Tine R, Abiola A, Ndiaye M, Ndiaye JL, Ndiaye D, Sokhna C, Gomis JF, Dieng Y, Faye O, Ndir O, Milligan P, Cairns M, Hallett R, Sutherland C, Gaye O (2013). Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malar J. 12:137.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref32">
				<label>32</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Macdonald G (1957). The epidemiology and control of malaria. Oxford University Press, London, United Kingdom.]]>
				</mixed-citation>
			</ref>
						<ref id="ref33">
				<label>33</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Marks F, Meyer CG, Sievertsen J, TimmannCEvans J, Horstmann RD, May J (2004). Genotyping of Plasmodium falciparum pyrimethamine resistance by matrix-assisted laser desorptionionization time-of-flight mass spectrometry. Antimicrob. Agents Chemother. 48(2):466-72.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref34">
				<label>34</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, Mandomando I, Puyol L, Berzosa P, Doba-o C, Aide P, Sacarlal J, Benito A, Alonso P, Menndez C (2008). Molecular markers of resistance to sulfadoxinepyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J. Infect. Dis. 197(12):1737-42.
					4]]>
				</mixed-citation>
			</ref>
						<ref id="ref35">
				<label>35</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[McElroy PD, Beier JC, Oster CN, Onyango FK, Oloo AJ, Lin X, Beadle C, Hoffman SL (1997). Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. Am. J. Epidemiol. 145(10):945-56.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref36">
				<label>36</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, Ziniel P, Dzisi SY, Frempong M, Agana-Nsiire P, Amoo-Sakyi F, Otchwemah R, Cramer JP, Anemana SD, Dietz E, Bienzle U (2007). Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob. Agents Chemother. 51(9):3273-81.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref37">
				<label>37</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Molineaux L (1997). Natures experiment: what implications for malaria prevention? Lancet 349:1636-7.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref38">
				<label>38</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, Nkya W, Kataraihya J, Abdulla S, Beck HP, Mshinda H (2004). Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am. J. Trop. Med. Hyg. 71:696-702.]]>
				</mixed-citation>
			</ref>
						<ref id="ref39">
				<label>39</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Nfor ENMW, Njifutri N, Mbulli IA, Taw B, Masumbi NP, Venyoka A (2007). Evaluation de la chimiorsistance  la sulfadoxine-pyrimethamine et des mutations des genes dhfr et dhps dans le district de sante de Ndu au nord-ouest Cameroun. Afr. J. Sci. Tech. 8:52-55.Image]]>
				</mixed-citation>
			</ref>
						<ref id="ref40">
				<label>40</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM (1998). Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42:164-9.]]>
				</mixed-citation>
			</ref>
						<ref id="ref41">
				<label>41</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Omar SA, Adagu IS, Warhurst DC (2001). Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans. R. Soc. Trop. Med. Hyg. 95:315-9.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref42">
				<label>42</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Patil AP, Okiro EA, Gething PW, Guerra CA, Sharma SK, Snow RW and Hay SI (2009). Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation. Malar. J. 8:186.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref43">
				<label>43</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Quelhas D, Puyol L, Quint L, Serra-casa E, Nhampossa T, Macete E, Aide P, Mayor A, Mandomando I, Sanz S, Aponte JJ, Chauhan VS, Chitnis CE, Alonso PL, Menndez C and Doba-o C (2008). Impact of intermittent preventive treatment with sulfadoxinepyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin. Vaccine Immunol. 15(8):1282-91.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref44">
				<label>44</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF (1996). Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg. 55:209-13.]]>
				</mixed-citation>
			</ref>
						<ref id="ref45">
				<label>45</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, Stein C, Nahlen BI, Bryce J, Black RE, Steketee RW (2006). The burden of malaria mortality among African children in the year 2000. Int. J. Epidemiol. 35(3):691-704.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref46">
				<label>46</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H, Alonso P (2005). Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365(9469):1481-3.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref47">
				<label>47</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Schreiber N, Kobbe R, Adjei S, Adjei O, Klinkert MQ, May J (2007). Immune responses after single-dose sulphadoxinepyrimethamine indicate under- estimation of protective efficacy of intermittent preventive treatment in infants. Trop. Med. Int. Health 12(10):1157-63.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref48">
				<label>48</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Sesay S, Milligan P, Touray E, Sowe M, Webb EL, Greenwood BM, Bojang KA (2011). A trial of intermittent preventive treatment and home-based management of malaria in a rural area of the Gambia. Malar. J. 10:2.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref49">
				<label>49</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM and Nzila AM (2001). Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17:582-8.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref50">
				<label>50</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV (1997). Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. USA. 94:1124-9.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref51">
				<label>51</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta S, Marsh K (1997). Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349(9066):1650-4.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref52">
				<label>52</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Sokhna C, Cisse B, B el H, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D, Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF (2008). A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One. 3(1):e1471.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref53">
				<label>53</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Som AF, Zongo I, Compaor YD, Sakand S, Nosten F, Oudraogo JB, Rosenthal PJ (2014). Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 58(7):3660-5.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref54">
				<label>54</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Sutherland CJ, Drakeley CJ, Schellenberg D (2007). How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar. J. 6:161.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref55">
				<label>55</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Triglia T, Cowman AF (1999). The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resist. Updat. 2:15-9.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref56">
				<label>56</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Vekemans J, Ballou WR (2008). Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines 7(2):223-40.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref57">
				<label>57</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Wipasa J, Riley EM (2007). The immunological challenges of malaria vaccine development. Expert Opin. Biol. Ther. 7(12):1841-52.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref58">
				<label>58</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[World Health Organization (WHO) (2000). Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl 1):S1-90.
					]]>
				</mixed-citation>
			</ref>
						<ref id="ref59">
				<label>59</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[World Health Organization (WHO) (2008). The World Malaria Report 2008.
				
					View]]>
				</mixed-citation>
			</ref>
						<ref id="ref60">
				<label>60</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[World Health Organization (WHO) (2010). Global report on antimalarial drug efficacy and drugresistance 2000-2010.
				
					View]]>
				</mixed-citation>
			</ref>
						<ref id="ref61">
				<label>61</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[World Health Organization (WHO) (2011). The World Malaria Report 2011.
				
					View]]>
				</mixed-citation>
			</ref>
						<ref id="ref62">
				<label>62</label>
				<mixed-citation publication-type="other" xlink:type="simple">
				<![CDATA[Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, Rosenthal PJ, Sutherland C, Nosten F, Ouedraogo JB (2015). Randomized Non-inferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 59(8):4387-96.
					]]>
				</mixed-citation>
			</ref>
					</ref-list>
	</back>
    </article>